Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00177775 · ClinicalTrials.gov registry record · Phase 2

Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea

A Phase 2 study, sponsored by University of Pittsburgh.

Terminated
Registry status
Phase 2
Development phase
60
Enrollment target

NCT00177775 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00177775, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.

TERMINATED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

The primary objective of this study is to assess the safety of the investigational agent, MucoMilk®, a polyclonal-antibody enriched Whey Protein Concentrate 40% (WPC-40) made of milk of immunized cows. Secondary objectives will investigate the effectiveness of MucoMilk® as an aid in the prevention of relapse of C. difficile-associated diarrhea (CDAD).

Interventions

  • DRUG MucoMilk product

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2005-04
Est. Completion 2005-08
Phase Phase 2

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT00177775

The ClinicalTrials.gov registry entry for NCT00177775 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which MucoMilk product is the first listed.

NCT00177775 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00177775 about?

NCT00177775 is a clinical study titled "Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea". The primary objective of this study is to assess the safety of the investigational agent, MucoMilk®, a polyclonal-antibody enriched Whey Protein Concentrate 40% (WPC-40) made of milk of immunized cows. Secondary objectives will investigate the effectiveness of MucoMilk® as an aid in the prevention o...

What is the current status of trial NCT00177775?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-04. Estimated completion is 2005-08.

What interventions are being tested in trial NCT00177775?

The interventions under investigation include: MucoMilk product (DRUG).

Who is sponsoring clinical trial NCT00177775?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.